| 價格 | 詢價 |
| 包裝 | 1支 |
| 最小起訂量 | 1支 |
| 發(fā)貨地 | 湖北 |
| 更新日期 | 2026-05-06 |
| 中文名稱:SPOP (2B14)兔單抗 | 英文名稱:SPOP (2B14) Rabbit Monoclonal Antibody |
| 品牌: EnkiLife | 產(chǎn)地: 中國 |
| 產(chǎn)品類別: 抗體 | |
| 是否進口: 否 | 用途: 科研 |
產(chǎn)品概述
產(chǎn)品性能
免疫原
產(chǎn)品應(yīng)用
研究背景
Inhibits IPF1/PDX1 transactivation of established target promoters, such as insulin, may be by recruiting a repressor complex (By similarity). In complex with CUL3, involved in ubiquitination of BMI1, H2AFY and DAXX, and probably also in ubiquitination and proteasomal degradation of Gli2 or Gli3. Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation. In complex with CUL3, involved in ubiquitination and proteasomal degradation of BRMS1, DAXX, PDX1/IPF1, GLI2 and GLI3. In complex with CUL3, involved in ubiquitination of MACROH2A1 and BMI1; this does not lead to their proteasomal degradation. Inhibits transcriptional activation of PDX1/IPF1 targets, such as insulin, by promoting PDX1/IPF1 degradation. The cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOP has higher ubiquitin ligase activity than the complex that contains the heterodimer formed by SPOP and SPOPL. Involved in the regulation of bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4 stability (PubMed:32109420).
研究領(lǐng)域
| 成立日期 | 2024-08-02 (2年) | 注冊資本 | 271萬人民幣 |
| 員工人數(shù) | 10-50人 | 年營業(yè)額 | ¥ 100萬-300萬 |
| 主營行業(yè) | 生化試劑,抗體,細胞培養(yǎng),癌癥研究,細胞生物學 | 經(jīng)營模式 | 工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥3870 |
VIP1年
|
上海西格生物科技有限公司
|
2026-06-18 | |
| 詢價 |
VIP5年
|
上海優(yōu)寧維生物科技股份有限公司
|
2026-06-18 | |
| 詢價 |
碧云天生物技術(shù)有限公司
|
2026-06-09 |